\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
(Reuters) – The following is a summary of some recent studies on COVID-19. They come with studies that deserve further examination to corroborate the effects and have yet been rated through peer review.
Compared to the previous subvariant of Omicron BA. 2, the newly dominant Omicron BA. 5 is linked to a higher likelihood of causing momentary SARS-COV-2 infection, regardless of vaccination status, a Portuguese study suggests.
From last April to early June, the researchers studied 15,396 adults inflamed with the BA. 2 variant and 12,306 inflamed with BA. 5. Vaccines and boosters were equally effective compared to either subline, according to a report published Monday in medRxiv ahead of the peer review. However, 10% of BA. 5 cases were reinfections, compared with 5. 6% of BA. 2 cases, suggesting a relief in coverage conferred by past infections compared to BA. 5 compared to BA. 2, the researchers said. In addition, the vaccines gave the impression of being less effective in reducing the threat of serious outcomes for BA. 5 compared to BA. 2.
“Among other people inflamed with BA. 5, booster vaccination was associated with 77% and 88% relief in the risk of hospitalization and death from COVID-19, respectively, while greater risk relief was found for BA. 2 cases, at 93% and 94%, respectively,” the researchers wrote. While “COVID-19 booster vaccination still provides really broad coverage as opposed to serious consequences after BA. 5 infection,” they said, their findings provide “evidence to adjust the public’s fitness measures. “Ba. 5” surge.
The spike protein on its surface that the coronavirus uses to penetrate core muscle cells also triggers an attack on the immune system, according to new research.
The sars-CoV-2 spike protein interacts with other proteins in cardiac myocytes to cause inflammation, researchers said Wednesday in a presentation at the American Heart Association’s 2022 Basic Cardiovascular Science Science Sessions. Spike-CoV2 and spike proteins from a different relatively innocent coronavirus, the researchers found that only the SARS-CoV-2 spike protein caused cardiac dysfunction, hypertrophy and inflammation. In addition, they found that in the mobile muscles of the inflamed center, only the peak of SARS-CoV-2 interacted with so-called TLR4 (Toll-4 receptor) proteins that recognize invaders and elicit inflammatory responses. In a deceased patient with COVID-19 inflammation, researchers discovered sars-CoV-2 spike protein and TLR4 protein in central muscle mobiles and other types of mobiles. Both were absent from a biopsy from a healthy human center.
“This means that once the center becomes inflamed with SARS-CoV-2, it will activate TLR4 signaling,” Zhiqiang Lin of the Masonic Medical Research Institute in Utica, New York, said in a statement. “We have provided direct evidence that the spike protein is poisonous to central muscle cells and has reduced the underlying mechanism because the spike protein inflames central muscle cells,” he told Reuters. “
A new mixture of monoclonal antibodies can save it and treat Omicron infections in monkeys, researchers reported Monday in Nature Microbiology.
The antibodies, called P2G3 and P5C3, recognize express regions of the spike protein that the SARS-CoV-2 virus uses to enter cells. “P5C3 can block all variants of SARS-CoV-2 that dominated the pandemic up to Omicron BA. 2,” said Dr. Didier Trono, from the Swiss Institute of Technology in Lausanne. “So, P2G3 comes to the rescue because not only can it neutralize all the past variants of SARS-CoV-2 fear, but it can also block BA. 4 and BA. . 5,” he said. P2G3 is even effective against some BA. 2 or BA. 4/BA. 5 mutants capable of escaping from bebtélovimab (Eli Lilly), the only clinically approved antibody that continues to exhibit activity opposite to the newly dominant BA. 4/BA. 5 subvariants. “
In laboratory experiments, mutations that can make SARS-CoV-2 variants resistant to P2G3 failed to escape P5C3, and P5C3 escape mutants were still blocked through P2G3, Trono said. gaps of the other and vice versa. “
Aerium Therapeutics plans to start testing the combination in humans next month, said Trono, who is among the company’s founders. months to other people who are immunocompromised and do not have a strong reaction to COVID-19 vaccines, the company said.
Click to get a Reuters Global COVID-19 Tracker https://graphics. reuters. com/world-coronavirus-tracker-and-maps/index. html and for a Reuters COVID-19 Vaccination Tracker https://graphics. reuters. com /world-coronavirus-tracker-and-maps/vaccination-rollout-and-access.
(Reports by Nancy Lapid; Editing via Bill Berkrot)